Bone Marrow and Stem Cell Transplant in Turkey: Donors, Cost & Hospitals

A bone marrow transplant in Turkey, more accurately called a hematopoietic stem cell transplant (HSCT), replaces or restores blood-forming stem cells.

These stem cells produce:

Red blood cells White blood cells Platelets

The term “bone marrow transplant” remains widely used, but many modern transplants use hematopoietic stem cells collected from the bloodstream rather than directly from bone marrow.

The treatment generally takes place in several stages.

Transplant assessment

The hematology team first confirms the diagnosis, disease status and reason transplantation is being considered.

The patient's heart, lungs, liver, kidneys and infection status are evaluated to determine whether they can tolerate conditioning treatment and transplantation.

Donor selection or autologous collection

For an autologous transplant, the patient's own stem cells are mobilised and collected before high-dose treatment.

For an allogeneic transplant, the team searches for the most appropriate donor.

This may include:

Matched sibling Other related donor Haploidentical family donor Matched unrelated donor Alternative donor source

Conditioning treatment

The patient receives chemotherapy and, in some protocols, radiotherapy.

Conditioning can:

Destroy malignant cells Suppress the recipient's immune system Create space for transplanted stem cells Reduce the risk that donor cells will be rejected

Stem-cell infusion

The transplant day is often called Day 0.

The stem-cell product is infused through a central venous catheter, similar to receiving a blood transfusion.

The patient is normally awake during this part of treatment.

Engraftment

The infused stem cells circulate through the bloodstream and migrate into the bone marrow.

The medical team then waits for the cells to begin producing new blood cells.

This process is called engraftment.

Immune recovery

Blood-count recovery does not mean the immune system is fully restored.

Immune recovery can take many months, particularly after an allogeneic transplant.

Types of stem cell transplant in Turkey

A bone marrow or stem cell transplant may be considered when transplantation offers a meaningful advantage over other available treatment.

Eligibility depends on much more than the patient's diagnosis.

The transplant team considers:

Disease typeDisease stageResponse to previous treatmentRelapse riskAgeFunctional statusHeart functionLung functionLiver functionKidney functionInfection historyPrevious treatmentDonor availabilityConditions commonly considered for hematopoietic stem cell transplantation include: Acute myeloid leukaemiaAcute lymphoblastic leukaemiaSelected chronic leukaemiasMyelodysplastic syndromesHodgkin lymphomaNon-Hodgkin lymphomaMultiple myelomaAplastic anaemiaThalassaemiaSickle cell diseaseFanconi anaemiaCertain severe immune deficienciesSelected inherited metabolic diseasesOther bone marrow failure syndromes Not every patient with one of these conditions needs transplantation. For example, some patients with leukaemia may benefit from allogeneic transplantation only when the disease has certain high-risk features or after particular treatment responses. Similarly, autologous transplantation may be more appropriate than donor transplantation for selected lymphoma or multiple myeloma patients. Candidate assessment table

A transplant decision may depend on:

Whether the disease is in remissionExpected relapse riskAvailability of an appropriate donorPrevious chemotherapyPrevious transplantOrgan functionSerious infectionsGeneral physical conditionAbility to tolerate conditioning

An allogeneic donor requires a separate evaluation focused on both donor safety and recipient compatibility.

The first major consideration is HLA matching.

Human leukocyte antigens are proteins that help the immune system distinguish the body's own cells from foreign cells.

A close HLA match generally reduces certain transplant risks, although modern transplant techniques allow transplantation using partially matched donors in selected circumstances.

A potential donor may be:

A matched siblingAnother related donorA haploidentical relativeAn unrelated volunteer identified through TÜRKÖK or another registry

A family relationship is therefore helpful in some cases but not legally or medically required for all allogeneic transplantation.

Donor evaluation

Peripheral blood stem-cell collection

Many allogeneic stem cells are collected from peripheral blood.

The donor generally receives medication for several days to increase the number of blood-forming stem cells circulating in the bloodstream.

The cells are then collected through apheresis.

Blood passes through a machine that separates the stem cells while the remaining blood components are returned to the donor.

Bone marrow collection

Stem cells can alternatively be collected directly from the pelvic bone marrow.

This usually takes place under anaesthesia in an operating room.

Neither collection method removes the donor's entire bone marrow.

The body replaces the donated cells.

EndFragment

The transplant assessment is usually more extensive than routine cancer treatment because both disease status and the patient's ability to tolerate transplantation must be evaluated.

International patients may send many records before travelling to Turkey, but the transplant centre can repeat key investigations before final approval.

**Recipient and donor *testing***

Bone marrow biopsy

A recent bone marrow biopsy may be necessary to determine:

Disease burdenRemission statusMarrow cellularityCytogenetic findingsMolecular disease markers HLA typing

HLA testing is essential when an allogeneic transplant is planned.

Testing may first be performed on:

SiblingsParentsChildrenOther potentially suitable relatives

If no appropriate family donor is found, an unrelated donor search may be initiated through TÜRKÖK and international donor registries.

Infection screening

Infection screening is critical because conditioning treatment and post-transplant immunosuppression can severely weaken immune defence.

Testing is tailored to the patient's history and transplant protocol.

The bone marrow transplant cost in Turkey varies according to the transplant type, diagnosis, donor source, donor-registry requirements, conditioning regimen, hospital stay and complications.

An autologous transplant usually has a different cost structure from an allogeneic transplant because it does not require an external donor.

The current verified price shown below is pulled directly from our transplant price registry rather than hard-coded into the article.

A bone marrow and stem cell transplant in Turkey should be carried out in a specialised hematopoietic stem cell transplantation centre with appropriate authorisation, trained staff, infection-control facilities, laboratory support and access to blood products.

Turkey separately regulates bone marrow transplant centres and also regulates the collection, testing, processing, storage, transport and cross-border movement of human tissues and cells.

Modern HSCT centres may provide:

Autologous transplantationAllogeneic transplantationHaploidentical transplantationRelated donor transplantationUnrelated donor transplantation

Not every centre performs every transplant type.

Some hospitals have separate adult and paediatric programs.

The hospitals displayed below are generated from our verified provider and price registry rather than being manually selected.

A hospital appears only after its bone marrow or stem cell transplant service and relevant price record have been verified.

Patients should still confirm that the centre treats their specific disease and transplant type.

Hematopoietic stem cell transplantation requires a multidisciplinary team.

The doctors displayed below are linked to their verified hospital affiliations and transplant roles in our provider database.

The team may include:

HematologistsPediatric hematologistsHematology-oncology specialistsInfectious disease physiciansIntensive care specialistsTransfusion medicine specialistsApheresis specialistsLaboratory specialistsPathologistsRadiologistsPharmacistsNutrition specialistsTransplant nursesTransplant coordinators

For allogeneic transplantation, expertise in graft-versus-host disease, donor selection and immune management is particularly important.

A doctor's presence on this page should indicate verified involvement in hematopoietic stem cell transplantation rather than general oncology alone.

Hospital stay after a bone marrow or stem cell transplant is very different from recovery after ordinary surgery.

The stem-cell infusion itself may take only a relatively short time, but the patient can remain medically vulnerable for weeks while waiting for engraftment.

Patients typically enter the transplant unit before Day 0 for conditioning treatment.

After the stem cells are infused, blood counts fall to very low levels before the new marrow begins producing blood cells.

During this period, infection and bleeding risks are increased.

Some patients remain in protective inpatient care for several weeks, although the exact duration varies substantially according to:

Autologous vs allogeneic transplantConditioning regimenSpeed of engraftmentInfectionGraft-versus-host diseaseDisease statusGeneral health

Typical transplant timeline

A patient may be discharged before the immune system has fully recovered.

International patients may therefore need to remain near the transplant centre after leaving hospital.

International HSCT requires more planning than many other forms of medical treatment abroad.

Before travelling, the transplant centre should review the patient's diagnosis, pathology, previous treatment, disease status and possible donor options.

For an autologous transplant, the key issue is usually whether the patient is medically suitable for mobilisation, stem-cell collection and high-dose conditioning.

For an allogeneic transplant, donor availability must also be considered.

If an unrelated donor is required, donor searches and confirmatory HLA testing may take time and should not be assumed to be completed immediately after arrival.

Stem cells may also need to be transported between countries under controlled conditions.

Turkey's current tissue and cell regulations include provisions relating to transportation, traceability, import and export of human cellular products.

International patients should not book a short fixed trip based only on the transplant infusion date.

The most medically vulnerable phase occurs after the infusion.

During early recovery, patients may require frequent:

Blood countsDrug-level monitoringInfection testingElectrolyte monitoringTransfusionsGVHD assessments

For allogeneic patients in particular, the first 100 days after transplantation are an important monitoring period.

Before returning home, the patient should have:

A discharge summaryTransplant reportDonor and graft information where appropriateCurrent medication listImmunosuppressive scheduleLatest laboratory resultsInfection-prevention planFollow-up scheduleVaccination plan when appropriateEmergency contact detailsA hematologist in the home country

The Turkish transplant centre should confirm when international travel is medically safe.

The medical risks of a bone marrow and stem cell transplant in Turkey are the same fundamental risks associated with hematopoietic stem cell transplantation internationally. HSCT is an intensive treatment, and the level of risk varies according to the disease, age, transplant type, donor compatibility, conditioning regimen, previous treatment and overall health.

Infection is one of the most important early risks. Conditioning therapy temporarily suppresses or destroys much of the patient's existing blood-forming and immune system. Until the transplanted stem cells engraft and immune function begins to recover, bacterial, viral and fungal infections can become serious very quickly.

Patients can also develop severe anaemia, low platelet counts and very low white blood cell counts. Blood and platelet transfusions may be required while the new marrow begins functioning.

Conditioning chemotherapy can cause nausea, diarrhoea, mouth inflammation, hair loss, fatigue and loss of appetite. More serious toxicity can affect the liver, kidneys, lungs, heart or nervous system.

Allogeneic transplantation carries the additional risk of graft-versus-host disease (GVHD). GVHD occurs when immune cells from the donor recognise the recipient's tissues as foreign and attack them. Acute GVHD commonly affects the skin, gastrointestinal tract and liver, while chronic GVHD can affect many organs and may require prolonged immunosuppressive treatment.

Engraftment can occasionally be delayed or fail. If donor cells do not establish adequate blood production, additional treatment or another cellular infusion may be required.

The underlying cancer or blood disorder can also return after transplantation. Relapse risk depends heavily on the disease, molecular features and disease status at the time of transplant.

Long-term complications may include infertility, hormonal disorders, bone disease, cataracts, chronic GVHD, organ dysfunction and an increased risk of certain secondary cancers.

For international patients, continuity of care after leaving Turkey is particularly important because significant complications can develop weeks or months after the transplant. A clear handover to a hematologist experienced in post-transplant care should be arranged before the patient returns home.